Back

Tumor-Derived SPP1 Drives Immunosuppressive Macrophage Reprogramming in Gastric Peritoneal Carcinomatosis

Turcios, L.; Hosamani, N.; Beswick, E. J.; Ubil, E.; Carey, M.; Leinwand, J.; Nomura, S.; Yan, J.; Evers, M. B.; Kim, J.; Barry-Hundeyin, M.

2026-07-08 cancer biology
10.64898/2026.06.21.733605 bioRxiv
Show abstract

Peritoneal carcinomatosis is a major cause of death in gastric cancer, yet effective therapies remain limited. Tumor-derived soluble factors are increasingly recognized as key regulators of the peritumoral microenvironment. Here, we nominate osteopontin (SPP1) as a tumor-derived mediator that orchestrates macrophage-driven immunoregulation in gastric peritoneal carcinomatosis. Using integrated analyses of human clinical datasets and murine models, we demonstrate that tumor-secreted SPP1 promotes macrophage recruitment and induces tolerogenic IL-10 production. Clinically, SPP1 correlated with inferior overall survival and progression-free survival in gastric cancer. In syngeneic murine models of gastric peritoneal carcinomatosis, intracavitary pharmacologic inhibition of SPP1 restricted peritoneal dissemination, impaired macrophage infiltration and suppressed IL-10 production. Consistent with these findings, macrophage depletion phenocopied antitumor effects of SPP1 inhibition, resulting in decreased metastatic burden. Collectively, these findings define a mechanism of tumor-macrophage crosstalk that promotes peritoneal dissemination and provide a rationale for therapeutic targeting of SPP1 in gastric peritoneal carcinomatosis.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Cancer Research
130 papers in training set
Top 0.1%
11.6%
2
Nature Communications
5641 papers in training set
Top 18%
9.6%
3
Journal of Clinical Investigation
179 papers in training set
Top 0.3%
7.7%
4
Cancer Discovery
66 papers in training set
Top 0.3%
6.6%
5
Cancer Cell
42 papers in training set
Top 0.1%
6.6%
6
Gastroenterology
42 papers in training set
Top 0.2%
4.2%
7
Clinical Cancer Research
64 papers in training set
Top 0.5%
4.0%
50% of probability mass above
8
Oncogene
85 papers in training set
Top 0.6%
3.2%
9
JCI Insight
277 papers in training set
Top 2%
3.2%
10
Journal for ImmunoTherapy of Cancer
75 papers in training set
Top 0.8%
3.1%
11
Cancer Immunology Research
35 papers in training set
Top 0.4%
2.7%
12
Nature Cancer
39 papers in training set
Top 0.6%
2.7%
13
Molecular Cancer Therapeutics
40 papers in training set
Top 0.4%
2.4%
14
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 25%
2.1%
15
Cell Reports
1498 papers in training set
Top 17%
2.1%
16
Journal of Experimental Medicine
119 papers in training set
Top 1%
1.9%
17
Science Translational Medicine
127 papers in training set
Top 2%
1.7%
18
Cellular and Molecular Gastroenterology and Hepatology
46 papers in training set
Top 0.6%
1.7%
19
eLife
5828 papers in training set
Top 59%
1.1%
20
Molecular Cancer Research
49 papers in training set
Top 1%
1.1%
21
Cell Death & Disease
21 papers in training set
Top 0.3%
1.1%
22
Cancer Letters
35 papers in training set
Top 0.9%
1.0%
23
Science Advances
1243 papers in training set
Top 28%
1.0%
24
Cell Communication and Signaling
51 papers in training set
Top 1%
0.8%
25
Cell Reports Medicine
153 papers in training set
Top 5%
0.8%
26
Genome Medicine
183 papers in training set
Top 6%
0.6%
27
Science Signaling
65 papers in training set
Top 2%
0.6%
28
Nature
645 papers in training set
Top 12%
0.6%
29
Immunity
67 papers in training set
Top 2%
0.6%